This clinical trial focuses on severe asthma, a condition where the airways in the lungs become inflamed and narrowed, making it difficult to breathe. The study examines the effects of stopping a medication called Dupixent (also known as dupilumab), which is used to treat severe asthma. Dupixent is given as a solution for injection under the skin using a pre-filled syringe.
The purpose of the study is to compare the outcomes of patients who stop taking Dupixent with those who continue using it. Participants in the study have been using Dupixent for at least three years and have their asthma well-controlled. The study will observe these patients over a period of 24 months to see if stopping the medication affects their asthma control.
Throughout the study, researchers will monitor the participants’ asthma symptoms and any changes in their condition. They will look at factors such as the number of asthma flare-ups, changes in asthma control scores, and whether patients need to restart Dupixent or switch to another treatment. The goal is to understand if stopping Dupixent is as effective as continuing it for patients with well-controlled severe asthma.
France 
